A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies (Q33372218)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies |
scientific article |
Statements
1 reference
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies (English)
1 reference
Hagop Kantarjian
1 reference
Jorge Cortes
1 reference
Farhad Ravandi
1 reference
Francis Giles
1 reference
Guillermo Garcia-Manero
1 reference
Maher Albitar
1 reference
Kapil Bhalla
1 reference
Margaret Dugan
1 reference
Thomas Fischer
1 reference
Joachim Beck
1 reference
Eric Masson
1 reference
Patricia Rae
1 reference
Glen Laird
1 reference
Sunil Sharma
1 reference
1 reference
Identifiers
1 reference